Background: Colorectal cancer (CRC) is a common human malignancy. The aims of this study are to investigate the gene expression profile of CRC and to explore potential strategy for CRC diagnosis, therapy and prognosis. Methods: We use affy and Limma package of Bioconductor R to do differential expression genes (DEGs) and differential expression lncRNAs (DELs) analysis from the gene datasets (GSE8671, GSE21510, GSE32323, GSE39582 and TCGA) respectively. Then, DEGs were analyzed by GO and KEGG pathway and Kaplan-Meier survival curve and Cox regression analyses were used to find aberrantly expressed genes associated with survival outcome of CRC patients. Real-time PCR assay was used to verify the aberrantly expressed genes expression in CRC samples. Results: 306 up-regulation and 213 down-regulation common DEGs were found. A total of 485 DELs were identified, of which 241 up-regulated and 244 down-regulated. Then, GO and KEGG pathway analyses showed that DEGs were involved in cell cycle, mineral absorption, DNA replication, and Nitrogen metabolism. Among them, Kaplan-Meier survival curve and Cox regression analyses revealed that CDC6, CDC45, ORC6 and SNHG7 levels were significantly associated with survival outcome of CRC patients. Finally, real-time PCR assay was used to verify that the CDC6, CDC45, ORC6 and SNHG7 expression were upregulated in 198 CRC samples compared with the expression levels in individual-matched adjacent mucosa samples. Conclusion: CDC6, CDC45, ORC6 and SNHG7 are implicated in CRC initiation and progression and could be explored as potential diagnosis, therapy and prognosis targets for CRC.
Background
Colorectal cancer (CRC) is one of the most frequently diagnosed cancer and a leading cause of cancer-related mortality worldwide, with approximately 1.4 million cases and 693,900 deaths in 2012. 1 Risk factors for colorectal cancer can be divided into two aspects: Non-modifiable risk factors and Modifiable risk factors. 2 Main non-modifiable risk factors are age, sex, ethnicity, family history, hereditary syndrome, prior adenomatous or sessile serrated polyp, inflammatory bowel disease, diabetes mellitus and BRCA mutations. 2, 3 Unhealthy lifestyles, including consuming red and processed meat, obesity, smoking and alcohol consumption, are main modifiable risk factors. 2, 4 The stage of the patient at the time of diagnosis is one of the most important factors affecting the prognosis of patients with colorectal cancer. In the United States, localized stage CRC is diagnosed in 39% of patients, for which the 5-year survival rate is 90%. The survival rate declines to 71% and 14% for patients diagnosed with regional and distant-stage disease, respectively. 5 Although advances in surgical techniques and adjuvant chemotherapies have improved the clinical outcomes in recent years, the prognosis of advancedstaged patients remains frustrating. 6 Therefore, the study of the mechanisms of colorectal cancer is essential. It is urgent to find potential strategy for CRC diagnosis and prognosis.
With the advancement of technologies, genome-wide molecular profiling has been used to screen and identify key genes in several cancer. 7, 8 In this study, we aimed to identify differentially messenger RNAs (mRNAs) and expressed lncRNAs in CRC by analyzing GEO and TCGA database. 519 common differential expression genes (DEGs) were detected from four GEO datasets and 485 differential expression lncRNAs (DELs) were screened from TCGA. To provide novel information about molecular mechanisms and functional roles of mRNAs, we sent DEGs to DAVID database (https:// david.ncifcrf.gov/) to perform the Gene Ontology (GO) and pathway analysis. Further analysis revealed that cell division cycle (CDC) 6, CDC45, origin recognition complex (ORC) 6 and small nucleolar RNA host gene (SNHG) 7 were significantly upregulated in malignant tissues and associated with survival outcome of colorectal cancer patients by Kaplan-Meier survival curve and Cox regression analyses. And we chose these four genes to verify the analysis results in 199 paired colorectal cancer tissues. These results suggest that CDC6, CDC45, ORC6 and SNHG7 might be associated with CRC, and serve as potential strategy for CRC diagnosis and prognosis.
Methods

Colorectal Cancer Datasets
The discovery datasets GSE8671, 
Identification of DEGs
The raw data of GSE8671, GSE21510, GSE32323, GSE39582 and TCGA were separately preprocessed by affy package of Bioconductor R (http://www.bioconductororg/packages/ release/bioc/html/affy.html). Expression values were achieved after background correction, quantile normalization, and the summarization of probe set values into one expression measure. 13, 14 The DEG analysis between tumor and nontumor samples of the GSE8671, GSE21510, GSE32323, and GSE39582 datasets and the DELs between tumor and nontumor of TCGA dataset were performed with the 
Results
Identification of DEGs and DELs
By applying bioinformatics analysis, we investigated DEGs between CRC and non-cancer samples of the GEO dataset (GSE8671, GSE21510, GSE32323 and GSE39582). Analysis results showed 560 up-regulated and 704 down-regulated DEGs in GSE8671 ( Figure 1A ), 1817 up-regulated and 1217 down-regulated DEGs in GSE21510 ( Figure 1B ), 1950 upregulated and 518 down-regulated DEGs in GSE32323 ( Figure 1C ), and 1332 up-regulated and 785 down-regulated DEGs in GSE39582 ( Figure 1D ). Further analysis revealed 519 common DEGs in the four datasets, consisting of 306 upregulated and 213 down-regulated genes ( Figure 1E and F). Next, we investigated the DELs between 622 CRC and 55 normal samples of the TCGA RNA-seq dataset. Based on the cut-off point (p-Value < 0.05 and count ≥ 2), we found a total of 485 DELs, including 241 up-regulated and 244 downregulated ( Figure 1G ).
Functional Enrichment Analysis of DEGs
GO analysis was performed to determine biological functions of the 519 DEGs. According to the GO analysis, DEGs were enriched in biological process, mainly involved in cell division (p=4.11E-15) and mitotic nuclear division (p=9.67E-15). Genes associated with molecular function were mainly related to protein binding (p=5.39E-06) and chemokine activity (p=4.20E-05).
In cellular components, spindle pole (p=6.25E-06) and condensed chromosome kinetochore (p=9.20E-06) were the top two GO terms (Figure 2A Figure 2D and Table 2 ).
The Expression of CDC6, CDC45, ORC6 and lncRNA SNHG7 in Colorectal Cancer Datasets
We chose the genes CDC6, CDC45, ORC6 and lncRNA SNHG7 for further study due to their important role in functional analysis and their prognostic value ( Figure 3 ) in CRC patients. Analysis of the four GEO datasets revealed that CDC6, CDC45 and ORC6 were overexpressed in CRC tissues compared to non-cancerous tissues ( Figure 4 ). Further analysis was found that CDC6 and CDC45 might be associated with TNM stage, lymph node metastasis and distant metastasis (Table 3) . And the expression of ORC6 was associated with invasion depth (Table 3 ). High expression of CDC6, CDC45 and ORC6 in CRC tissues was further confirmed by analysis of a TCGA database with 622 CRC tissues and 51 noncancerous tissues ( Figure 5 ). At the same time, we found that lncRNA SNHG7 was also highly expressed in CRC tissues compared to non-tumor tissues in the TCGA dataset ( Figure 5 ). However, we have not found the connection between the SNHG7 and TNM stage, invasion depth, lymph node metastasis and distant metastasis (Table 4) .
CDC6, CDC45, ORC6 and lncRNA SNHG7 Expression as Prognostic Indicators for Colorectal Cancer
Next, we evaluated the correlation between the DEGs and DELs expression and CRC patient's prognosis by KaplanMeier survival analysis in the GSE39582 and TCGA datasets. Patients were divided into high expression and low expression groups based on the mean value of expression. As shown in Figure 6 , in CRC samples of GSE39582, patients with CDC6, CDC45 or ORC6 low expression in the tumor samples had significantly worse relapse-free survival (RFS) (P<0.001, hazard ratio 2.555, 95% CI: 1.775-3.678 for CDC6, Figure 6A ; P <0.001, hazard ratio: 1.916, 95% CI: 1.380-2.659 for CDC45, Figure 6B ; P =0.0168, hazard ratio: 1.490, 95% CI: 1.074-2.067 for ORC6, Figure 6C ) and overall survival (OS) (P=0.0033, hazard ratio 1.543, 95% CI: 1.155-2.061 for CDC6, Figure  6D ; P = 0.0459, hazard ratio: 1.341, 95% CI: 1.005-1.788 for CDC45, Figure 6E ) based on a 250 days follow-up. We further analyzed the associations of CDC6, CDC45 and ORC6 expression with OS and relapse-free survival (RFS) in the TCGA dataset. As shown in Figure 3 , patients with either a low CDC6 or a low CDC45 expression had significantly poorer OS and earlier recurrence. However, there was no significant association between ORC6 expression and the OS and RFS of CRC samples in TCGA (P >0.05, Supplementary Figure 1) . Meanwhile, we found that the OS of CRC patients with high lncRNA SNHG7 expression was significantly worse than that with low lncRNA SNHG7 expression ( Figure 3E ).
Moreover, univariate Cox regression analysis of RFS of the CRC cases in GSE39582 showed that low CDC6, CDC45 or ORC6 expression (P <0.001), TNM stage (I/II vs. III/IV; P <0.001), lymph node metastasis (N0, N1/N2), as well as depth of tumor invasion (T1/T2, T3/T4) were risk factors that affect prognosis (Table 5) . Subsequent multivariate analysis revealed that low CDC6, CDC45, and ORC6 expressions were the independent prognosis factors affecting RFS of CRC patients, in addition to TNM stage, lymph node metastasis, and tumor invasion depth. Furthermore, multivariate analyses of CRC samples within TCGA indicated that SNHG7 expression, distant metastasis, and TNM stage were three independent prognostic risk factors affecting the OS of patients with CRC (Table 6 ). These data indicated that upregulated SNHG7 and down-regulated CDC6, CDC45 and ORC6 could to predict prognosis in CRC patients. 
Real-Time PCR Validation of DEGs and DEL
In order to verify the DEGs of the analysis, we performed RT-PCR of CDC6, CDC45, ORC6, and SNHG7 in 198 paired CRC and adjacent mucosa samples. CDC6, CDC45, ORC6, and SNHG7 expression levels in cancer samples were significantly higher than those in non-cancer samples (CDC6, P<0.0001, Figure 7A ; CDC45, P<0.0001, Figure 7B ; ORC6, P<0.0001, Figure 7C ; SNHG7, P<0.0001, Figure 7D ). Subsequently, we explored the correlation of CDC6, CDC45, ORC6, and SNHG7 expression levels with the clinicopathological factors in CRC patients. As shown in Figure 8 , the CDC6 expression level was remarkably correlated with T stage, N stage, and TNM stage ( Figure 8A) ; the CDC45 level was significantly associated with T stage and TNM stage ( Figure 8B) ; the ORC6 level was remarkably correlated with N stage ( Figure 8C) ; and the SNHG7 level was significantly associated with M stage ( Figure 8D ). In addition, a positive correlation between the lncRNA SNHG7 level and the CDC6/CDC45/ORC6 levels was observed in CRC tissues (Figure 9 ).
Diagnostic Performance of mRNA and lncRNA Levels for the Differentiation of CRC Patients from Healthy Controls
The potential diagnostic utility of SNHG7, CDC6, CDC45 and ORC6 to differentiate between CRC and benign disease was assessed through generating a receiver operating characteristic (ROC) curve for SNHG7, CDC6, CDC45 and ORC6 expression. We found that the ROC area under curve (AUC) of the SNHG7 was 0.84 (95% confidence interval (CI): 0.81-0.88); the CDC6 was 0.88 (95% CI: 0.84-0.91); the CDC45 was 0.82 (95% CI: 0.-78-0.86); the ORC6 was 0.85 (95% CI, 082-0.89) ( Figure 10 ). However, we do not have serum sample to verify our point, considerable work needs to be done. 
Discussion
In the present study, we identified the significantly differentially expressed mRNAs and lncRNAs in CRC by using GSE8671, GSE21510, GSE32323, GSE39582 and TCGA database. After analysis, 519 common DEGs and 485 DELs were screened. GO and KEGG pathway analyses showed that DEGs were associated with CRC progression. According to the GO analysis, DEGs were enriched in cell division, mitotic nuclear division, protein binding, chemokine activity, spindle and condensed chromosome kinetochore. Pathway analyses revealed that the DEGs were mainly involved in cell cycle, mineral absorption, DNA replication, nitrogen metabolism, proximal tubule bicarbonate reclamation, hematopoietic cell lineage and ribosome biogenesis in eukaryotes. Given their important roles in the prognostic value in patient with CRC, CDC6, CDC45, ORC6 and SNHG7 were selected for further study. Kaplan-Meier analysis and further univariates Cox regression analysis revealed that CDC6, CDC45, ORC6 and SNHG7 were associated with the OS or RFS of patient with CRC and might be the independent prognosis biomarkers for CRC patients. Our analysis indicated that the dysregulated DEGs were significantly enriched in cell cycle. Cancer is characterized by deregulated proliferative signaling resulting from aberrant cell cycle activity. Therefore, cell cycle regulators have been considered as potential targets for cancer therapy. 24 CDC6, CDC45, and ORC6 are three DEGs involved in cell cycle regulation. CDC6 functions as a regulator at the early steps of DNA replication. It localizes in the nucleus during cell cycle G1 29 and osteosarcoma. 30 In addition, CDC6 may be a promising target for overcoming CDDP resistance in bladder cancer, 31 oxaliplatin resistance for CRC 32 and paclitaxel resistance for gastric cancer. 33 As a DNA replication initiation factor, Cdc45 directly interacts with MCM7 and DNA polymerase alpha in the assembly of the highly conserved multiprotein complex that includes Cdc6/Cdc18, the MCMs, and DNA polymerase; the assembly of the complex is essential for the initiation of eukaryotic DNA replication. [28] [29] [30] CDC45 might be the target of miR-34a and a potential therapeutic target of CRC. 34 In non-small cell lung cancer (NSCLC), downregulation of CDC45 induced G2/M phase cell cycle arrest and inhibited cell proliferation both in vitro and in vivo, which might act as an oncogene in NSCLC.
35
ORC6 is one of the six subunits of the ORC, which includes a core complex consisting of ORC2, ORC3, ORC4, and ORC5, loosely interacting with ORC6 and ORC1 Reduction of ORC6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin. ORC6 may be a potential novel target for future anti-cancer therapy in colon cancer. 36 LncRNAs, which comprise more than 200 nucleotides in length and lack a significant open reading frame, have been reported to act as critical factors in cancer development and progression. 37 Our studies also identified differentially expressed lncRNAs in CRC based on gene expression profiling and focused on the lncRNAs SNHG7 for further analysis. SNHG7 is located on chromosome 9q34.3, with a length of 2157 bp, which has been known to be upregulated in several cancers. LncRNA-SNHG7 acts as a ceRNA for miR-193b and attenuates the inhibitory effect of miR-193b on FAIM2, which promotes the proliferation, migration and invasion, and inhibits apoptosis of lung cancer cells. 38, 39 LncRNA-SNHG7 also regulates proliferation, apoptosis, and invasion of bladder cancer cells, 40 gastric cancer cells, 41 and esophageal cancer cells. 42 In osteosarcoma, SNHG7 promotes the tumor growth and epithelial-to-mesenchymal transition by miR-34a. 43 SNHG7 promotes the proliferation, migration, and invasion of glioblastoma cells through inhibition of miR-5095 and concomitant activation of Wnt/β-catenin signaling pathway. 44 It accelerates prostate cancer proliferation and cell cycle progression through cyclin D1 by sponging miR-503. 45 In addition, recent studies have revealed that SNHG7 played a major role in CRC. Long non-coding RNA-SNHG7 acted as a target for miR-34a to increase the GALNT7 level 46 and sponged miR-216b to upregulate GALNT1 47 in CRC.
According to the functional analysis and prognostic value, we chose CDC6, CDC45, ORC6 and SNHG7 to conduct real-time PCR in 198 paired CRC and adjacent mucosa samples. Results revealed that these genes levels in cancerous tissues were significantly higher than noncancer samples and correlated with CRC T/N/M stage. In addition, the level of SNHG7 was positively correlated with the CDC6, CDC45 and ORC6 mRNA. These implied that SNHG7 might affect the cell cycle of CRC by regulating the expression of CDC6, CDC45 or ORC6. However, we do not have prognostic data for CRC samples, and the prognostic impact of CDC6, CDC45, ORC6 and SNHG7 on colorectal cancer was not verified in our samples. In addition, the expressions of CDC6, CDC45 and ORC6 were higher in cancerous samples than adjacent mucosa samples, but patients with CDC6, CDC45 or ORC6 low expression in the tumor samples had worse prognostic. These genes might play different roles at different stages of CRC. 48, 49 They might act as oncogenes in the early stage but have suppressor effects on cancer in the advanced stage.
Conclusion
We identified 519 DEGs and 485 DELs as candidate biomarkers for the diagnosis of CRC by gene expression profile analysis. Further study revealed that CDC6, CDC45, ORC6 and SNHG7 were up-regulated in CRC and could be the independent prognosis factors for CRC. These results implied that these four genes might involve with CRC initiation and progression and could be explored as potential diagnosis, therapeutic and prognostic targets for CRC.
